Accommodating our 10-year commitment to reproducibility of GxP insights as we transition from proprietary to open source backboned data science

[epijim]

Discussed in #1

^{Originally posted by epijim May 2, 2023}
Many companies are working to embrace open source, and a shift to fully open sourced studies - but a clinical trial can run for 5+ years, and a health authority may request further work after a trial closes.

This has led to three types of work being present:

• completely next gen work (e.g. studies 100% R/Python)
• mixed studies (e.g. initial work in SAS, later work in R/Python, or a split where data work in SAS, later reporting event in R)
• legacy studies (e.g. 100% SAS)

Ensuring all three are possible has important impacts on people and platforms, and brings complexity to our roadmaps. What can we learn from each other enabling these workflows?